Key Takeaways:
WILMINGTON, Del. – Prelude Therapeutics Incorporated (Nasdaq: PRLD) announced the pricing of an underwritten offering to raise approximately $90 million in gross proceeds through the sale of common stock and pre-funded warrants.
The offering, announced via a company press release, is expected to close on or about April 21, 2026, subject to customary closing conditions.
The clinical-stage precision oncology company is offering 18,018,014 shares of its voting common stock at a price of $4.44 per share. For certain investors, the offering includes pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per warrant.
The offering is likely to cause short-term downward pressure on Prelude's stock price due to the dilution of existing shareholders. The infusion of capital, however, strengthens the company's balance sheet and provides crucial funding for its clinical-stage precision oncology programs.
This capital raise provides Prelude with an extended cash runway to advance its pipeline of cancer therapies. Investors will be watching for the successful closing of the offering around April 21, 2026, as the next key event.
This article is for informational purposes only and does not constitute investment advice.
